Several studies implied that patients’ responses to blocking antibodies for PD-1/PD-L1 were strongly associated with both the intratumoral level of PD-L1 and the status of their tumor microenvironment (TME) (7, 8). This evidence concerns the gene PDCD1 and neoplasm.